Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
|ClinicalTrials.gov Identifier: NCT00003763|
Recruitment Status : Completed
First Posted : July 22, 2004
Last Update Posted : April 4, 2017
RATIONALE: Diagnostic procedures using the drug radiolabeled folic acid and imaging may be effective in detecting ovarian cancer.
PURPOSE: Diagnostic trial to study the effectiveness of radiolabeled folic acid plus imaging in detecting ovarian cancer.
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer||Procedure: radionuclide imaging Radiation: indium In 111 folic acid||Not Applicable|
OBJECTIVES: I. Evaluate the effectiveness of folic acid conjugated with indium In 111 to diagnose ovarian cancer and locate metastatic disease.
OUTLINE: This is a diagnostic study. Patients receive an injection of folic acid conjugated with indium In 111. The patient then undergoes imaging studies at various time points (e.g., 1, 4, and 24 hours). Patients then undergo exploratory surgery, the results of which are then compared to the imaging studies.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Study to Determine the Ability of Folate Conjugates to Target Folate Receptors in Ovarian Cancer Tumors|
|Study Start Date :||January 1999|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003763
|United States, Indiana|
|Indiana University Cancer Center|
|Indianapolis, Indiana, United States, 46202-5265|
|United States, Missouri|
|Washington University - St. Louis|
|St. Louis, Missouri, United States, 63110|
|United States, Texas|
|University of Texas - MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Study Chair:||David M. Gershenson, MD||M.D. Anderson Cancer Center|